Locus Biosciences
Clinical-stage biotechnology company developing precision bacteriophage-based therapeutics using an automation and AI-driven discovery platform, synthetic biology and GMP manufacturing to address antibiotic-resistant bacterial infections and related indications.
Industries
Nr. of Employees
medium (51-250)
Locus Biosciences
Patents
Products
Investigational CRISPR-enhanced bacteriophage therapy targeting E. coli (clinical-stage)
Clinical-stage investigational bacteriophage cocktail engineered with a CRISPR-based construct to target Escherichia coli, combining phage lytic activity and targeted genomic disruption to treat infections such as urinary tract infections.
Investigational CRISPR-enhanced bacteriophage therapy targeting E. coli (clinical-stage)
Clinical-stage investigational bacteriophage cocktail engineered with a CRISPR-based construct to target Escherichia coli, combining phage lytic activity and targeted genomic disruption to treat infections such as urinary tract infections.
Services
Platform services that combine automated laboratory workflows with AI/ML to support surveillance, discovery, cocktail optimization, and development workflows for bacteriophage therapeutics.
Platform services that combine automated laboratory workflows with AI/ML to support surveillance, discovery, cocktail optimization, and development workflows for bacteriophage therapeutics.
Expertise Areas
- Engineered bacteriophage therapeutics
- AI/ML-driven therapeutic discovery
- Clinical development and trial execution for biologics
- GMP biomanufacturing and scale-up
Key Technologies
- CRISPR-Cas nucleic-acid targeting
- Bacteriophage engineering
- Artificial intelligence / machine learning
- Next-generation sequencing and genomic analysis
News & Updates
Reported award of $3.3M from NIH to support a clinical trial of an AI-designed bacteriophage therapy for pneumonia caused by antibiotic-resistant bacteria.
Announcement of a research collaboration to develop precision antibacterial therapies for ophthalmic infections.
Announcement of release of $23.9M under a BARDA contract to support continuation of clinical development of a CRISPR-enhanced bacteriophage therapy for E. coli urinary tract infections, and details on the ELIMINATE Phase 2 study design and Part 1 results.
Reported award of $3.3M from NIH to support a clinical trial of an AI-designed bacteriophage therapy for pneumonia caused by antibiotic-resistant bacteria.
Announcement of a research collaboration to develop precision antibacterial therapies for ophthalmic infections.
Announcement of release of $23.9M under a BARDA contract to support continuation of clinical development of a CRISPR-enhanced bacteriophage therapy for E. coli urinary tract infections, and details on the ELIMINATE Phase 2 study design and Part 1 results.